Efficacy and Safety of Cinacalcet in the Treatment of Hemodialysis Patients with Secondary Hyperparathy-roidism:A Systematic Review
10.6039/j.issn.1001-0408.2016.21.19
- VernacularTitle:西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进症有效性和安全性的系统评价
- Author:
Shujie LI
;
Shiwei RUAN
;
Yuliang QIU
;
Hualing LI
;
Xiaojing XUE
;
Yawen CHEN
;
Dengpiao XIE
;
Lixiang ZHANG
;
Long WAN
- Publication Type:Journal Article
- Keywords:
Cinacalcet;
Hemodialysis;
SHPT;
Meta-Analysis
- From:
China Pharmacy
2016;27(21):2937-2940,2941
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the efficacy and safety of cinacalcet in the treatment of hemodialysis pa-tients with secondary hyperparathyroidism,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from Medline,Cochrane Library,EMBase and CBM,randomized controlled trials(RCT)about cinacalcet in the treatment of he-modialysis patients with secondary hyperparathyroidism (SHPT) were collected. Meta-analysis was performed by using Rev Man 5.3.5 software after data extract and quality evaluation by Cochrane systematic Rev Man 5.3.5. RESULTS:Totally 7 RCTs were en-rolled,involving 1 987 patients. Results of Meta-analysis showed cinacalcet can significantly reduce the rate of surgical parathyroid-ectomy[RR=0.23,95%CI(0.06,0.89),P=0.03],incidence of fracture[RR=0.26,95%CI(0.12,0.60),P=0.002] and increase the incidences of hypocalcemia[RR=9.81,95%CI(3.92,4.59),P<0.001],nausea[RR=1.97,95%CI(1.58,2.46),P<0.001] and vomit-ing[RR=1.91,95%CI(1.50,2.42),P<0.001],while it showed no significant effect on the the incidence of all-cause mortality and cardiovascular death. CONCLUSIONS:The clinical efficacy of cinacalcet in the treatment of hemodialysis patients with secondary hyperparathyroidism is good,but there are common adverse reactions such as nausea and vomiting,hypocalcemia.
